# Safety and Efficacy of Neuromultivit in Treatment of Vertebrogenic Radiculopathy

> **NCT02508805** · PHASE3 · COMPLETED · sponsor: **Bausch Health Americas, Inc.** · enrollment: 100 (actual)

## Conditions studied

- Vertebrogenic Radiculopathy L5, S1

## Interventions

- **DRUG:** Neuromultivit
- **DRUG:** Voltaren
- **DRUG:** Sirdalud

## Key facts

- **NCT ID:** NCT02508805
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2015-09
- **Final completion:** 2015-11
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2017-05-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02508805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02508805, "Safety and Efficacy of Neuromultivit in Treatment of Vertebrogenic Radiculopathy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02508805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*